{"id":30349,"date":"2025-04-09T11:49:15","date_gmt":"2025-04-09T01:49:15","guid":{"rendered":"https:\/\/template.reachmarkets.com.au\/investorportal\/?p=30349"},"modified":"2025-04-11T13:51:30","modified_gmt":"2025-04-11T03:51:30","slug":"dr-james-campbell-qa-update","status":"publish","type":"post","link":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/","title":{"rendered":"Dr James Campbell Q&#038;A Update"},"content":{"rendered":"\n<section id=\"investor-briefing\" class=\"wp-block-gutentor-m3 section-gm7eb22c4 gutentor-module gutentor-container-cover has-image-bg has-custom-bg\"><div class=\"grid-container\">\n<section id=\"gmdc05e34\" class=\"wp-block-gutentor-m4 section-gmdc05e34 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmccec98\" class=\"wp-block-gutentor-m4-col col-gmccec98 gutentor-single-column  grid-lg-12 grid-md-12 grid-12\"><div id=\"section-gmccec98\" class=\"section-gmccec98 gutentor-col-wrap\">\n<h2 class=\"wp-block-heading has-text-align-center has-white-color has-text-color\" style=\"font-size:33px\">Prescient Therapeutics: Q&amp;A Update with Dr James Campbell<\/h2>\n\n\n\n<div style=\"height:30px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"gmee625ac\" class=\"wp-block-gutentor-m4 section-gmee625ac gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gmbc5118\" class=\"wp-block-gutentor-m4-col col-gmbc5118 gutentor-single-column  grid-lg-7 grid-md-6 grid-12\"><div id=\"section-gmbc5118\" class=\"section-gmbc5118 gutentor-col-wrap\">\n<figure class=\"wp-block-image size-full showvi\"><img loading=\"lazy\" decoding=\"async\" width=\"650\" height=\"360\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\" alt=\"\" class=\"wp-image-30352\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png 650w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1-300x166.png 300w\" sizes=\"auto, (max-width: 650px) 100vw, 650px\" \/><\/figure>\n\n\n\n<script src=\"https:\/\/ajax.googleapis.com\/ajax\/libs\/jquery\/3.5.1\/jquery.min.js\"><\/script>\n<script type=\"text\/javascript\"> \njQuery(document).ready(function ($) {\n    $('.showvi').click(function(e) {\n    e.preventDefault();\n  $('.showvi').html('<iframe loading=\"lazy\" src=\"https:\/\/player.vimeo.com\/video\/1074488944?title=0&#038;byline=0&#038;portrait=0\" width=\"100%\" height=\"410\" frameborder=\"0\" allow=\"autoplay; fullscreen\" allowfullscreen><\/iframe>');\n});\n});\n\n <\/script>\n<script type=\"text\/javascript\">jQuery(document).ready(function($){\n    $(\".showvi\").append(\"<img class='play-icon play-video' src='https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2022\/07\/playvideo-3-1.svg' \/>\");\n});<\/script>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm551378\" class=\"wp-block-gutentor-m4-col col-gm551378 gutentor-single-column  grid-lg-5 grid-md-6 grid-12 homepage-custom\"><div id=\"section-gm551378\" class=\"section-gm551378 gutentor-col-wrap\">\n<p class=\"has-white-color has-text-color\">Reach Markets recently interviewed Dr James Campbell regarding his newly appointment position as Non-Executive Chairman.<\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">In this session, Dr James Campbell discusses:<\/p>\n\n\n\n<ul class=\"wp-block-list white\">\n<li>Why he stepped up as Chair and his focus over the next 12 months.<\/li>\n\n\n\n<li>Key milestones for PTX-100 as we progress into Phase 2 clinical trials.<\/li>\n\n\n\n<li>Building a strong, Australia-based team with a focus on cost efficiency that will allow PTX to go deep into Phase 2.<\/li>\n<\/ul>\n\n\n\n<p><\/p>\n\n\n\n<p class=\"has-white-color has-text-color\">Recorded on 9 April 2025 at 12:00pm (AEST)<\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/investor-briefing\/\">Join the next Prescient Therapeutics webcast<\/a><\/p>\n\n\n\n<p><a href=\"https:\/\/template.reachmarkets.com.au\/investorportal\/register\/\">Register to stay up to date with Prescient Therapeutics<\/a><\/p>\n<\/div><\/div>\n<\/div><\/div><\/section>\n\n\n\n<section id=\"bio\" class=\"wp-block-gutentor-m3 alignwide section-gma2376a8 gutentor-module gutentor-container-cover custom-fullwidth\"><div class=\"grid-container\">\n<h4 class=\"wp-block-heading speak has-text-color\" style=\"color:#ffcc00\">Featured Speaker<\/h4>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n\n\n\n<section id=\"gma0d4f21\" class=\"wp-block-gutentor-m4 section-gma0d4f21 gutentor-module gutentor-advanced-columns\"><div class=\"grid-container\"><div class=\"grid-row\">\n<div id=\"col-gm0f1a2e\" class=\"wp-block-gutentor-m4-col col-gm0f1a2e gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm0f1a2e\" class=\"section-gm0f1a2e gutentor-col-wrap\"><\/div><\/div>\n\n\n\n<div id=\"col-gmb715e6\" class=\"wp-block-gutentor-m4-col col-gmb715e6 gutentor-single-column  grid-lg-6 grid-md-12 grid-12\"><div id=\"section-gmb715e6\" class=\"section-gmb715e6 gutentor-col-wrap\"><div class=\"wp-block-image speaker-img\">\n<figure class=\"aligncenter size-full\"><img loading=\"lazy\" decoding=\"async\" width=\"333\" height=\"342\" src=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/Dr-James-Campbell_PTX_2.png\" alt=\"\" class=\"wp-image-30353\" srcset=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/Dr-James-Campbell_PTX_2.png 333w, https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/Dr-James-Campbell_PTX_2-292x300.png 292w\" sizes=\"auto, (max-width: 333px) 100vw, 333px\" \/><\/figure>\n<\/div>\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\">Dr James Campbell<\/h3>\n\n\n\n<h4 class=\"wp-block-heading has-text-align-center speaker-title has-white-color has-text-color\">Non-Executive Chairman<\/h4>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\">Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. Dr. Campbell has more than 20 years of international biotechnology research, management and leadership experience and has been involved in the creation and\/or transformation of multiple successful Australian and international biotechnology companies.<br>He is currently CEO of Patrys Limited, a company developing novel antibody therapeutics for oncology.<br>He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011. His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.<br>Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.<\/p>\n\n\n\n<p class=\"has-text-align-center speaker-bio has-white-color has-text-color\"><\/p>\n<\/div><\/div>\n\n\n\n<div id=\"col-gm859df6\" class=\"wp-block-gutentor-m4-col col-gm859df6 gutentor-single-column  grid-lg-3 grid-md-12 grid-12\"><div id=\"section-gm859df6\" class=\"section-gm859df6 gutentor-col-wrap\">\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading has-text-align-center speaker-heading has-white-color has-text-color\"><\/h3>\n<\/div><\/div>\n<\/div><\/div><\/section>\n<\/div><\/section>\n<\/div><\/section>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":10,"featured_media":30352,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[29],"class_list":["post-30349","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-video","tag-prescient-therapeutics"],"gutentor_comment":0,"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Dr James Campbell Q&amp;A Update - PTX Therapeutics<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dr James Campbell Q&amp;A Update - PTX Therapeutics\" \/>\n<meta property=\"og:url\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\" \/>\n<meta property=\"og:site_name\" content=\"PTX Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T01:49:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-11T03:51:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"650\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Daniella Watson\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniella Watson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\"},\"author\":{\"name\":\"Daniella Watson\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"headline\":\"Dr James Campbell Q&#038;A Update\",\"datePublished\":\"2025-04-09T01:49:15+00:00\",\"dateModified\":\"2025-04-11T03:51:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\"},\"wordCount\":267,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\",\"keywords\":[\"Prescient Therapeutics\"],\"articleSection\":[\"Video\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\",\"name\":\"Dr James Campbell Q&A Update - PTX Therapeutics\",\"isPartOf\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\",\"datePublished\":\"2025-04-09T01:49:15+00:00\",\"dateModified\":\"2025-04-11T03:51:30+00:00\",\"author\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\"},\"breadcrumb\":{\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\",\"contentUrl\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png\",\"width\":650,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dr James Campbell Q&#038;A Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#website\",\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/\",\"name\":\"PTX Therapeutics\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d\",\"name\":\"Daniella Watson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g\",\"caption\":\"Daniella Watson\"},\"url\":\"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Dr James Campbell Q&A Update - PTX Therapeutics","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Dr James Campbell Q&A Update - PTX Therapeutics","og_url":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/","og_site_name":"PTX Therapeutics","article_published_time":"2025-04-09T01:49:15+00:00","article_modified_time":"2025-04-11T03:51:30+00:00","og_image":[{"width":650,"height":360,"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png","type":"image\/png"}],"author":"Daniella Watson","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniella Watson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#article","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/"},"author":{"name":"Daniella Watson","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"headline":"Dr James Campbell Q&#038;A Update","datePublished":"2025-04-09T01:49:15+00:00","dateModified":"2025-04-11T03:51:30+00:00","mainEntityOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/"},"wordCount":267,"commentCount":0,"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png","keywords":["Prescient Therapeutics"],"articleSection":["Video"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/","name":"Dr James Campbell Q&A Update - PTX Therapeutics","isPartOf":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage"},"image":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage"},"thumbnailUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png","datePublished":"2025-04-09T01:49:15+00:00","dateModified":"2025-04-11T03:51:30+00:00","author":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d"},"breadcrumb":{"@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#primaryimage","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png","contentUrl":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-content\/uploads\/2025\/04\/PTX-James-Campbell-1.png","width":650,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/dr-james-campbell-qa-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/template.reachmarkets.com.au\/investorportal\/"},{"@type":"ListItem","position":2,"name":"Dr James Campbell Q&#038;A Update"}]},{"@type":"WebSite","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#website","url":"https:\/\/template.reachmarkets.com.au\/investorportal\/","name":"PTX Therapeutics","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/template.reachmarkets.com.au\/investorportal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/template.reachmarkets.com.au\/investorportal\/#\/schema\/person\/4aae9d23fb2bf988bb3cc911a869c24d","name":"Daniella Watson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a7f9f6be6da4032f9e1867834f85f771d506fcb997cf479b6b4cb55683c78e64?s=96&d=mm&r=g","caption":"Daniella Watson"},"url":"https:\/\/template.reachmarkets.com.au\/investorportal\/author\/daniella\/"}]}},"_links":{"self":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30349","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/comments?post=30349"}],"version-history":[{"count":6,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30349\/revisions"}],"predecessor-version":[{"id":30359,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/posts\/30349\/revisions\/30359"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media\/30352"}],"wp:attachment":[{"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/media?parent=30349"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/categories?post=30349"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/template.reachmarkets.com.au\/investorportal\/wp-json\/wp\/v2\/tags?post=30349"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}